

REMARKS


Applicants amend claims 3 and 5 herein to correct errors in such claims. Specifically, while reviewing the subject application in preparation for payment of the issue fee Applicants noted that claim 3 provided for the sulfone linkage, described in the Examiner's reason for Allowance, to at times not be present. Claim 3 is corrected herein to provide that when $p = 2$ one of the independently selected Q substituents contains the sulfone linkage. Claim 5 is amended to delete several such species not containing the sulfone linkage.

Applicants note that the proposed Section 312 amendment does not introduce new matter into the claims nor raise new issues for prosecution. Rather, the amendment merely corrects an error in the claims. Applicants respectfully requests entry of the subject Section 312 amendment.

CONCLUSION

The points and concerns of the Examiner having been addressed in full, Applicants respectfully submit that the instant application is in condition for allowance, which action is respectfully requested. Should any issues remain unresolved in this application which would bar issuance the Examiner is invited to contact the undersigned Attorney at (919) 483-8247, to discuss such issues. Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to affect the timely filing of this paper the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

Respectfully submitted,


John L. Lemanowicz
Attorney for Applicants
Registration No. 37,380

Date: 14 December, 2006
Glaxo Smith Kline
Five Moore Drive, PO Box 13398
Research Triangle Park, North Carolina 27709
(919) 483-8247